TP53 and acute myeloid leukemia: Simultaneously, 18 gene variants were screened and integrated between s‐AML and de novo AML; TP53 (p = 0.003), U2AF1 (p = 0.049), SRSF2 (p = 0.029), and KDM5A (p = 0.019) mutations displayed higher frequencies in s‐AML (Table 8, Figure 8B).